Cordyceps Sunshine Biotech Holdings (RAJAF) Accumulated Expenses (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $85074.0 for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 162.49% year-over-year to $85074.0; the TTM figure through Dec 2025 stood at $85074.0 (up 162.49% YoY), while the FY2025 annual figure was $85074.0, up 162.49% from the prior year.
• Accumulated Expenses was $85074.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from $32410.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $85074.0 in Q4 2025 to a low of $26889.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $52706.8 across 5 years, with a median of $56407.0 in 2021.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses tumbled 57.15% in 2023, then jumped 162.49% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $56407.0 in 2021, then grew by 11.25% to $62754.0 in 2022, then sank by 57.15% to $26889.0 in 2023, then increased by 20.53% to $32410.0 in 2024, then surged by 162.49% to $85074.0 in 2025.
• The last three Accumulated Expenses figures came in at $85074.0 (Q4 2025), $32410.0 (Q4 2024), and $26889.0 (Q4 2023), per Business Quant data.